Influenza diagnosis and treatment: Impact of new antivirals on perceived treatment behaviours during recent influenza outbreaks

Clinical Drug Investigation

Volumn 23, Issue 1, 2003, Pages 11-20

  Schatz L ^a,c   Cloarec, S ^b   Laude, S ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b GfK Group   (Germany)

^c Roche Pharma Schweiz AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHILL; CONSULTATION; COUGHING; DISEASE SEVERITY; DRUG EFFECT; DRUG PREFERENCE; EPIDEMIC; FEMALE; FEVER; HEALTH BEHAVIOR; HEALTH CARE UTILIZATION; HUMAN; ILLNESS BEHAVIOR; INFLUENZA; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NORMAL HUMAN; PERCEPTION; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; SYMPTOM;

EID: 0037247278     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323010-00002     Document Type: Article

References (20)

1. Glezen WP, Decker M, Perotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987; 136: 550-5
2. Simonsen L, Schoenberger LB, Stroup DF, et al. The impact of influenza on mortality in the USA. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 26-33
3. LaForce FM, Nichol KL, Cox NJ. Influenza: virology, epidemiology, disease, and prevention. Am J Prev Med 1994; 10 (Suppl): 31-44
4. Benson V, Morano MA. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Vital Health Stat 1998; 10: 1-428
5. Cram P, Blitz SG, Monto A, et al. Influenza: cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmacoeconomics 2001; 19: 223-30
6. Meier CR, Napalkov PN, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834-42
7. Gubareva LV, Kaiser L, Hayden FG. Influenza neuraminidase inhibitors. Lancet 2000; 355: 827-35
8. Nicholson KG, Aoki FY, Osterhaus ADME, et al. Treatment of acute influenza: efficacy and safety of the oral neuraminidase inhibitor oseltamivir. Lancet 2000; 355: 1845-50
9. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003. In press
10. Ross AM, Kai J, Salter R, et al. Presentation with influenza-like-illness in general practice: implications for use of neuraminidase inhibitors. Commun Dis Public Health 2000; 3: 256-60
11. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80
12. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61
13. Mäkelä MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000; 40: 42-8
14. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283: 1016-24
15. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-33
16. Snacken R and the Influenza Diagnosis Working Party. Managing influenza in primary care: a practical guide to clinical diagnosis. Dis Manage Health Outcomes 2000; 8: 79-85
17. Van Elden LJ, van Essen GA, Boucher CA, et al. Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice. Br J Gen Pract 2001; 51: 630-4
18. Monto A, Napalkov P, Wegmüller Y. Medical resources utilisation for influenza-related complications in a large health insurance plan [abstract 11.008]. 9th International Congress on Infectious Disease; 2000 Apr 10-13; Buenos Aires, Argentina. 15-6
19. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1178-87
20. Bricaire F, Cohen JM, Jacquet M, et al. Patient perspective on zanamivir in the treatment of influenza. Int J Clin Pract 2002; 56: 7-10